Courage Therapeutics' Dan Housman on Tackling Anorexia Nervosa
We really are able to do a lot once we get to the next point, because that's when we can build up all of these next-stage animal models in anorexia, animal models in larger animals than just a mouse, be able to test additional things.
Imagine being driven by personal experiences to create groundbreaking solutions for a devastating disorder. That’s exactly what Dan Housman, co-founder and CTO of Courage Therapeutics, is doing. In this episode, Dan shares his journey from molecular biology to biopharma, all inspired by his close encounters with eating disorders, specifically anorexia nervosa. He opens up about the inception of Courage Therapeutics and the company's mission to develop innovative treatments for this challenging condition.
Dan provides a candid look at the current landscape of eating disorder treatments and why they often fall short. He discusses the new drug his team is working on, designed to reduce the severity of anorexia symptoms and potentially minimize the need for more invasive treatments. The conversation also delves into the drug development process, offering listeners a peek into clinical trials and timelines.
If you’re interested in mental health, drug development, or simply want to understand more about the complexities of eating disorders, this episode is packed with valuable insights. Dan’s dedication and expertise make this a compelling listen for anyone seeking hope and innovation in mental health treatment.